These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7650235)

  • 1. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
    Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH
    J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
    Vachharajani NN; Shyu WC; Barbhaiya RH
    J Clin Pharmacol; 1997 Oct; 37(10):979-85. PubMed ID: 9505990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration.
    Vachharajani NN; Shyu WC; Nichola PS; Boulton DW
    Cephalalgia; 2002 May; 22(4):282-7. PubMed ID: 12100090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
    Shyu WC; Barbhaiya RH
    Br J Clin Pharmacol; 1996 Oct; 42(4):513-7. PubMed ID: 8904627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
    Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
    Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of sumatriptan nasal spray in adolescents.
    Christensen ML; Mottern RK; Jabbour JT; Fuseau E
    J Clin Pharmacol; 2003 Jul; 43(7):721-6. PubMed ID: 12856385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
    Davis GA; Rudy AC; Archer SM; Wermeling DP
    Am J Health Syst Pharm; 2004 Feb; 61(3):261-6. PubMed ID: 14986556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of sumatriptan nasal spray in children.
    Christensen ML; Mottern RK; Jabbour JT; Fuseau E
    J Clin Pharmacol; 2004 Apr; 44(4):359-67. PubMed ID: 15051742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02.
    Pal A; Gautam A; Munjal S
    J Clin Pharmacol; 2017 Nov; 57(11):1472-1478. PubMed ID: 28597922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
    Shyu WC; Morgenthien EA; Barbhaiya RH
    Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
    Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
    Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
    Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
    Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose phase I study of transnasal butorphanol.
    Shyu WC; Pittman KA; Robinson D; Barbhaiya RH
    Clin Pharmacol Ther; 1993 Jul; 54(1):34-41. PubMed ID: 8330463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
    Moore KH; Leese PT; McNeal S; Gray P; O'Quinn S; Bye C; Sale M
    Clin Ther; 2002 Apr; 24(4):583-94. PubMed ID: 12017403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
    Davis GA; Rudy AIa; Archer SM; Wermeling DP
    Am J Health Syst Pharm; 2005 Jan; 62(1):48-53. PubMed ID: 15658072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.